Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor

被引:44
作者
Cui, ZG [1 ]
Han, SJ [1 ]
Huang, L [1 ]
机构
[1] Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15213 USA
关键词
antigen-presenting cells; liposome; mannan; peptide; tumor vaccine;
D O I
10.1023/B:PHAM.0000029292.66792.4f
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Previously, our laboratory has reported that liposome-protamine-DNA (LPD) nanoparticle is an effective delivery system for tumor-associated antigens. Mannan, which potentially targets antigen-presenting cells, was coated on LPD to further enhance its antitumor activity. Methods. Cholesterol-conjugated mannan was coated on LPD. The abilities of mannan-coated LPD to target antigen-presenting cells, to activate dendritic cells, and to induce antitumor immunity were investigated and compared to those of LPD alone. Results. Both in vitro and in vivo uptake of LPD showed that mannan-coated LPD particles were preferably taken up by dendritic cells and macrophages. In addition, the expression of co-stimulatory molecules CD80/CD86 on DC2.4 cells after co-incubation with mannan-coated LPD was significantly higher than that after co-incubation with LPD. A model major histocompatibility complex class I restricted peptide antigen from HPV 16 E7 protein was incorporated into LPD to immunize mice against the growth of TC-1 tumor cells expressing E7 protein. Coating with mannan significantly enhanced both preventive and therapeutic activities of LPD/E7. Finally, the release of IFN-gamma from isolated splenocytes was significantly enhanced when mice were immunized with mannan-coated LPD/E7 than with LPD/E7 alone. Conclusion. Targeting of the LPD/E7 to local draining lymph nodes by mannan is partially responsible for the enhanced anti-tumor activity.
引用
收藏
页码:1018 / 1025
页数:8
相关论文
共 32 条
[1]   Advances in immunology - Vaccines and vaccination [J].
Ada, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (14) :1042-1053
[2]   DNA vaccination: Transfection and activation of dendritic cells as key events for immunity [J].
Akbari, O ;
Panjwani, N ;
Garcia, S ;
Tascon, R ;
Lowrie, D ;
Stockinger, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (01) :169-177
[3]   Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses [J].
Apostolopoulos, V ;
Barnes, N ;
Pietersz, GA ;
McKenzie, IFC .
VACCINE, 2000, 18 (27) :3174-3184
[4]   Expression of a mannose/fucose membrane lectin on human dendritic cells [J].
Avrameas, A ;
McIlroy, D ;
Hosmalin, A ;
Autran, B ;
Debre, P ;
Monsigny, M ;
Roche, AC ;
Midoux, P .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (02) :394-400
[5]  
Brown J C, 1978, Int Rev Cytol, V52, P277, DOI 10.1016/S0074-7696(08)60758-5
[6]   DNA-based immunization by in vivo transfection of dendritic cells [J].
Condon, C ;
Watkins, SC ;
Celluzzi, CM ;
Thompson, K ;
Falo, LD .
NATURE MEDICINE, 1996, 2 (10) :1122-1128
[7]   Topical immunization using nanoengineered genetic vaccines [J].
Cui, Z ;
Mumper, RJ .
JOURNAL OF CONTROLLED RELEASE, 2002, 81 (1-2) :173-184
[8]   Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses [J].
Dileo, J ;
Banerjee, R ;
Whitmore, M ;
Nayak, JV ;
Falo, LD ;
Huang, L .
MOLECULAR THERAPY, 2003, 7 (05) :640-648
[9]  
DITTGEN M, 1987, PHARMAZIE, V42, P641
[10]   The mannose receptor family [J].
East, L ;
Isacke, CM .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2002, 1572 (2-3) :364-386